AVITA Medical, Inc. (RCEL)
NASDAQ: RCEL · Real-Time Price · USD
3.790
-0.050 (-1.30%)
Nov 21, 2025, 4:00 PM EST - Market closed
AVITA Medical Revenue
AVITA Medical had revenue of $17.06M in the quarter ending September 30, 2025, a decrease of -12.71%. This brings the company's revenue in the last twelve months to $72.40M, up 20.59% year-over-year. In the year 2024, AVITA Medical had annual revenue of $64.25M with 28.14% growth.
Revenue (ttm)
$72.40M
Revenue Growth
+20.59%
P/S Ratio
1.40
Revenue / Employee
$278,465
Employees
260
Market Cap
115.57M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 64.25M | 14.11M | 28.14% |
| Dec 31, 2023 | 50.14M | 15.72M | 45.68% |
| Dec 31, 2022 | 34.42M | 1.40M | 4.23% |
| Dec 31, 2021 | 33.03M | 3.79M | 12.98% |
| Jun 30, 2021 | 29.23M | 14.97M | 104.95% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
RCEL News
- 9 days ago - AVITA Medical, Inc. (RCEL) Discusses Advanced Wound Care Solutions and Data-Driven Approaches in Clinical Healing Transcript - Seeking Alpha
- 15 days ago - AVITA Medical, Inc. (RCEL) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 18 days ago - Data Presented at the 2025 Southern Region Burn Conference Reinforce RECELL® System as a Standard of Care in Acute Wound Treatment - GlobeNewsWire
- 23 days ago - AVITA Medical to Announce Third Quarter 2025 Financial Results - GlobeNewsWire
- 24 days ago - AVITA Medical Welcomes Support for RECELL® in Burns in Australia - GlobeNewsWire
- 5 weeks ago - AVITA Medical Announces CEO Transition - GlobeNewsWire
- 5 weeks ago - AVITA MEDICAL INVESTIGATION: Bragar Eagel & Squire, P.C. Reminds AVITA Medical Investors to Contact the Firm Regarding the Ongoing Investigation on Behalf of Stockholders - GlobeNewsWire
- 6 weeks ago - AVITA REMINDER: Bragar Eagel & Squire, P.C. Reminds AVITA Medical Investors to Contact the Firm Regarding the Ongoing Investigation on Behalf of Stockholders - GlobeNewsWire